Dual antiplatelet Tx similar to aspirin post-CABG in diabetes

January 10, 2017

(HealthDay)—For post-coronary artery bypass grafting (CABG) patients with diabetes, cardiovascular and bleeding outcomes do not differ significantly with use of dual antiplatelet therapy (DAPT) versus aspirin, according to a study published in the Jan. 17 issue of the Journal of the American College of Cardiology.

Sean van Diepen, M.D., from the University of Alberta in Edmonton, Canada, and colleagues compared receiving DAPT (aspirin plus thienopyridine) and aspirin monotherapy at 30 days postoperatively in a post-hoc nonrandomized analysis from the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of multivessel disease (FREEDOM) trial. The primary outcome was the risk-adjusted five-year FREEDOM composite of all-cause mortality, nonfatal myocardial infarction, or stroke.

The researchers found that 68.4 and 31.6 percent of patients, respectively, received DAPT and aspirin alone at 30 days post-CABG. The five-year primary composite outcome did not differ significantly between DAPT- and aspirin-treated patients (12.6 versus 16 percent; adjusted hazard ratio, 0.83; 95 percent confidence interval, 0.54 to 1.27; P = 0.39). The five-year primary composite outcomes were similar for patients receiving DAPT versus aspirin alone in subgroups with pre-CABG and those with stable angina. There were no significant treatment-related differences between the groups in major , blood transfusions, or hospitalization for bleeding.

"The use of DAPT in patients with diabetes post-CABG in our cohort was high," the authors write. "Compared with monotherapy, no associated differences were observed in cardiovascular or bleeding outcomes, suggesting that routine use of DAPT may not be clinically warranted."

Two authors disclosed financial ties to the pharmaceutical industry.

Explore further: DAPT score improves risk prediction of continued DAPT

More information: Full Text
Editorial

Related Stories

DAPT score improves risk prediction of continued DAPT

June 1, 2016

(HealthDay)—A decision tool (dual antiplatelet therapy [DAPT] score) improves risk prediction for continued DAPT beyond assessment of myocardial infarction (MI) history, according to a study published in the May 31 issue ...

Six-month dual antiplatelet tx noninferior to 24-month DAPT

February 25, 2015

(HealthDay)—For aspirin-sensitive patients undergoing everolimus-eluting stent implantation, six-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT, according to a study published in the March 3 issue ...

DAPT use variable in patients with A-fib at risk of stroke

August 16, 2016

(HealthDay)—For patients with atrial fibrillation at moderate to high risk of stroke, dual antiplatelet therapy (DAPT) use is variable among those undergoing percutaneous coronary intervention (PCI), according to a study ...

Long duration dual antiplatelet treatment increases bleeding

October 1, 2015

(HealthDay)—Routine use of dual antiplatelet therapy (DAPT) beyond six months after second generation drug-eluting stent (DES) implantation yields mixed clinical results, according to a review published in the October issue ...

Adverse events not up with six months of DAPT

May 19, 2016

(HealthDay)—For patients receiving an everolimus-eluting stent implantation, six months of dual antiplatelet therapy (DAPT) does not increase composite events compared with 12 months of DAPT, according to a study published ...

Recommended for you

Nigeria: Clean-burning stoves improve health for new mothers

January 13, 2017

In a small clinical trial that replaced widely used biomass and kerosene cookstoves with clean-burning ethanol stoves, a team of researchers from the University of Chicago and the University of Ibadan (Nigeria) was able to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.